Revista da Associacao Medica Brasileira (1992) · 2026
Serum human epididymis protein 4, endocan, sialyl-Tn, and neopterin in endometrial cancer: a prospective case-control study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Toyran Atahan, Minareci Yagmur, Sözen Hamdullah, Kucukgergin Canan, Aydın Abdurrahman Fatih, Bingul İlknur, Gunver Mehmet Guven, Akkoyunlu Serra Zeynep, Topuz Samet, Salihoglu Mehmet Yavuz
Аннотация
OBJECTIVE: The aim of this study was to compare serum levels of endocan, human epididymis protein 4, sialyl-Tn antigen, and neopterin between women with endometrial cancer and asymptomatic healthy controls, and to explore their discriminatory performance in this case-control setting and clinicopathological associations.
METHODS: Prospective case-control study of 133 women with endometrial cancer and 65 healthy controls. Serum biomarkers were measured before treatment by enzyme-linked immunosorbent assays. Discrimination was evaluated using the area under the receiver operating characteristic curve with optimal cut-offs.
RESULTS: Endocan levels were significantly higher in endometrial cancer patients than in controls (p<0.001), with an area under the curve of 0.758. Serum human epididymis protein 4 was also elevated in patients (p<0.001), with an area under the curve of 0.702. Neopterin and sialyl-Tn did not differ significantly between groups. Endocan and human epididymis protein 4 were higher in women with lymphovascular space invasion (both p<0.05); however, these associations did not remain significant after correction for multiple comparisons.
CONCLUSION: Serum endocan and human epididymis protein 4 were elevated in endometrial cancer patients compared to asymptomatic healthy controls. Neopterin and sialyl-Tn showed no discriminatory value in this setting. Our findings should be interpreted as exploratory and require validation in clinically relevant cohorts.
METHODS: Prospective case-control study of 133 women with endometrial cancer and 65 healthy controls. Serum biomarkers were measured before treatment by enzyme-linked immunosorbent assays. Discrimination was evaluated using the area under the receiver operating characteristic curve with optimal cut-offs.
RESULTS: Endocan levels were significantly higher in endometrial cancer patients than in controls (p<0.001), with an area under the curve of 0.758. Serum human epididymis protein 4 was also elevated in patients (p<0.001), with an area under the curve of 0.702. Neopterin and sialyl-Tn did not differ significantly between groups. Endocan and human epididymis protein 4 were higher in women with lymphovascular space invasion (both p<0.05); however, these associations did not remain significant after correction for multiple comparisons.
CONCLUSION: Serum endocan and human epididymis protein 4 were elevated in endometrial cancer patients compared to asymptomatic healthy controls. Neopterin and sialyl-Tn showed no discriminatory value in this setting. Our findings should be interpreted as exploratory and require validation in clinically relevant cohorts.